- Active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or isn't responding to treatment. It compares a new medicine, etentamig, with existing treatments to see how well they control the cancer.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
This study is looking at a new combination treatment for myelofibrosis, a blood disorder. It combines a drug called Selinexor with Ruxolitinib to see if it's safe and helps people who haven't tried other similar treatments for myelofibrosis before.
For: MyelofibrosisUnited States · Australia · Belgium - Active not recruiting
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
This study looks at how a medicine called selinexor (Nexpovio®) works for people in the UK with a blood cancer called multiple myeloma that has come back or not responded to previous treatments. It aims to understand how patients feel, how safe the treatment is, and how well it works in everyday healthcare.
For: Multiple MyelomaAustria · Germany - Active not recruitingPHASE2
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
This study looks at a new drug, selinexor, for people with myelofibrosis whose current treatment hasn't worked well enough. It compares selinexor to standard care chosen by doctors to see if it's safe and effective.
For: MyelofibrosisUnited States · China · France - Active not recruitingPHASE3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
This study looks at a medicine called selinexor for people with advanced or recurring womb cancer (endometrial carcinoma). It's for patients whose cancer responded well to previous platinum-based treatment, to see if selinexor can help keep the cancer from coming back.
For: Endometrial CancerUnited States · Australia · Belgium